The Conference Forum is delighted to present the 2nd annual Rational Combinations 360°, the only event addressing business aspects, novel clinical trial designs and scientific deve
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh